Profiles

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

• CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22

• Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
• Assessment Procedures (refer to Section 4 in the Profile document - pg 30)

• FDG-PET/CT for Response to Cancer Therapy 2016-11-18

• UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12

• CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18

Stage 2: Consensus Profiles

• MR Diffusion-Weighted Imaging (DWI) 2019-12-20

• PET F-18 for Amyloid 2018-06-20

• MR Elastography of the Liver 2019-06-06

• SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1, 2017-06-26

• SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15

• Checklist - SPECT Profile Conformance

• MR DCE Quantification v1.0 2012-08-08

• CTA Atherosclerosis Biomarkers 2020-03-10

• SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21 (closed on February 3, 2020)

Stage 1: Public Comment Profiles

Please submit comments using the online form

• MSK Profile: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease (Open for comment: June 26, 2020 - September 29, 2020)

• MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29 (closed on May 15, 2020)

• US Shear Wave Speed for Liver Fibrosis 2019-10-21 (closed on December 18, 2019)

• Appendix E: SWS Checklists, 2019-10-21 (closed on December 18, 2019)

• CT Lung Density 2019-09-03 (Contains Conformance Checklist, Appendix B) (closed on October 16, 2019)

• Appendix E:CT Lung Density Protocols 2019-06-26 (closed on October 16, 2019)

• fMRI for Sensorimotor Mapping 2017-06-19 (Closed on December 31, 2017)

Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement

• Industry
• Clinical Sites
• Additional letters of support can be found here

See Also

• How to use QIBA Profiles
• Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
• Profile Conformance describes how sites and products claim conformance to a Profile.
• QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)

• Work Product for Review